Genome synthesis, assembly, and rebooting of therapeutically useful high G+C% mycobacteriophages

Bacteriophages show therapeutic promise for treating bacterial pathogens including nontuberculous mycobacteria (NTM). A major impediment is the paucity of therapeutically useful phages and the great variation in the phage infection profiles, especially among <i><i>Mycobacterium</i> abscessus</i> clinical isolates. These limitations-together with the abundance of mycobacteriophage genes of unknown function-could be addressed by synthetic genetic construction of viruses in which undesirable genes can be eliminated and genetic payloads can be readily added. However, the relatively high G+C% content of mycobacteriophage genomes (64.1%) can be challenging for DNA synthesis using phosphoramidite chemistry, and the genomes are relatively large (40 to 150 kbp) for assembly and rebooting in a bacterial host. Here, we demonstrate efficient de novo synthesis of high G+C% DNA fragments using terminal deoxynucleotidyl transferase chemistry, the reconstruction of complete mycobacteriophage genomes using High-Complexity Golden Gate Assembly, and efficient rebooting via electroporation into <i><i>Mycobacterium</i> smegmatis</i>. Using this approach, we synthesized the genomes of phages BPs (41.9 kbp, 66.6% G+C%) and Bxb1 (50.5 kbp, 63.6% G+C%), and constructed variants carrying targeted mutations or added payloads. Synthetic construction of mycobacteriophages and their derivatives expands the phage repertoire for therapeutic development and provides versatile tools for advancing mycobacterial genetics and phage-based clinical applications.

Authors

Institutions

Publication Details

Journal
Proceedings of the National Academy of Sciences
Published
2025-11-10
DOI
https://doi.org/10.1073/pnas.2523871122
Citations
5
Primary Topic
Bacteriophages and microbial interactions
Type
article
Field-Weighted Citation Impact
8.58

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Genome synthesis, assembly, and rebooting of therapeutically useful high G+C% mycobacteriophages

Gregory J. S. Lohman, Michael J. Lauer, Daniel A. Russell, Ching‐Chung Ko et al.
5 citations
Proceedings of the National Academy of Sciences
Bacteriophages and microbial interactions
8.58
article

Genome synthesis, assembly, and rebooting of therapeutically useful high G+C% mycobacteriophages

Gregory J. S. Lohman, Michael J. Lauer, Daniel A. Russell, Ching‐Chung Ko, Rebecca A. Garlena, Elizabeth D. Amarh, Nicole J. Chew, Graham F. Hatfull, Li Tan, Jared W. Ellefson, Andrew P. Sikkema, Ian T. Harrison
article en
5 citations

Abstract

Bacteriophages show therapeutic promise for treating bacterial pathogens including nontuberculous mycobacteria (NTM). A major impediment is the paucity of therapeutically useful phages and the great variation in the phage infection profiles, especially among <i><i>Mycobacterium</i> abscessus</i> clinical isolates. These limitations-together with the abundance of mycobacteriophage genes of unknown function-could be addressed by synthetic genetic construction of viruses in which undesirable genes can be eliminated and genetic payloads can be readily added. However, the relatively high G+C% content of mycobacteriophage genomes (64.1%) can be challenging for DNA synthesis using phosphoramidite chemistry, and the genomes are relatively large (40 to 150 kbp) for assembly and rebooting in a bacterial host. Here, we demonstrate efficient de novo synthesis of high G+C% DNA fragments using terminal deoxynucleotidyl transferase chemistry, the reconstruction of complete mycobacteriophage genomes using High-Complexity Golden Gate Assembly, and efficient rebooting via electroporation into <i><i>Mycobacterium</i> smegmatis</i>. Using this approach, we synthesized the genomes of phages BPs (41.9 kbp, 66.6% G+C%) and Bxb1 (50.5 kbp, 63.6% G+C%), and constructed variants carrying targeted mutations or added payloads. Synthetic construction of mycobacteriophages and their derivatives expands the phage repertoire for therapeutic development and provides versatile tools for advancing mycobacterial genetics and phage-based clinical applications.

Proceedings of the National Academy of SciencesVol. 122(46)
New England Biolabs (United States) (US), University of Pittsburgh (US), New England Biolabs (United Kingdom) (GB), OPX Biotechnologies (United States) (US), Raptamer Discovery Group (United States) (US)
National Institutes of Health
Openalex Percentile: Top 2%
Bacteriophages and microbial interactions
8.58
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.